[Table_MainInfo] 公司研究/造纸轻工 证券研究报告 明月镜片（301101）公司季报点评 2024 年 10 月 24 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | |-------------------------------------------------------------------------------------------------| | 股票数据 | | 10 [ Table_StockInfo 月 23 日收盘价（元） ] | | 52 周股价波动（元） | | 总股本 / 流通 A 股（百万股） | | 总市值 / 流通市值（百万元） | | 相关研究 | | [Table_ReportInfo] 《大单品延续增长趋势，"轻松控"系列产品 24H1 收入同增 39% 》 2024.08.25 | | 《 23 年"轻松控"产品同增 70% 持续优化》 2024.05.06 | | 《主营业务稳步增长，"轻松控"产品表现亮 眼》 2023.10.28 市场表现 | [Table_QuoteInfo] -38.27% -25. ...

[Main Financial Data](index=1&type=section&id=I.%20Main%20Financial%20Data) This section provides an overview of the company's key financial performance indicators and balance sheet items for the reporting period [Key Accounting Data and Financial Indicators](index=1&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved year-over-year growth in operating revenue and net profit attributable to shareholders for Q3 and YTD 2024, alongside steady increases in total assets and owner's equity | Indicator | Amount for Current Period (CNY) | YoY Change in Current Period | YTD Amount (CNY) | YTD YoY Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 198,262,404.64 | 0.64% | 583,282,748.51 | 3.61% | | Net Profit Attributable to Shareholders of Listed Company | 48,041,102.63 | 13.57% | 137,007,833.30 | 11.91% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains/Losses) | 41,981,589.43 | 15.22% | 117,479,581.19 | 9.88% | | Net Cash Flow from Operating Activities | -- | -- | 138,419,622.55 | -3.56% | | Basic Earnings Per Share (CNY/share) | 0.2384 | 13.58% | 0.6799 | 11.92% | | Diluted Earnings Per Share (CNY/share) | 0.2384 | 13.58% | 0.6799 | 11.92% | | Weighted Average Return on Net Assets | 2.99% | 0.23% | 8.57% | 0.48% | | **End of Current Period** | **End of Previous Year** | | **Change from End of Previous Year** | | | Total Assets (CNY) | 1,843,063,976.44 | 1,752,743,944.92 | | 5.15% | | Owner's Equity Attributable to Shareholders of Listed Company (CNY) | 1,633,315,398.36 | 1,556,526,892.00 | | 4.93% | [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Non-recurring gains and losses totaled CNY 6.06 million for the current period and CNY 19.53 million YTD, primarily from fair value changes of financial assets and government grants | Item | Amount for Current Period (CNY) | YTD Amount (CNY) | Notes | | :--- | :--- | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 66,562.95 | -229,250.18 | | | Government Grants Recognized in Current Profit/Loss | 1,109,493.68 | 4,936,957.24 | | | Gains/Losses from Fair Value Changes of Financial Assets and Liabilities Held by Non-Financial Enterprises, and from Disposal of Financial Assets and Liabilities | 5,955,594.68 | 17,175,611.90 | | | Reversal of Impairment Provisions for Receivables Subject to Separate Impairment Testing | 239,032.43 | 646,142.79 | | | Other Non-Operating Income and Expenses Apart from the Above | 68,753.54 | 750,272.47 | | | Less: Income Tax Impact | 1,251,603.01 | 3,581,552.99 | | | Impact on Minority Interests (After Tax) | 128,321.07 | 169,929.12 | | | Total | 6,059,513.20 | 19,528,252.11 | -- | [Changes and Reasons for Key Accounting Data and Financial Indicators](index=3&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Several financial indicators showed significant changes, including a 35.52% increase in R&D expenses, a 102.30% rise in financial expenses due to wealth management product adjustments, and substantial growth in investment and fair value change income Profit Statement Items | Item | YTD (CNY) | Prior Year Period (CNY) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | R&D Expenses | 23,006,274.11 | 16,976,361.63 | 35.52% | Primarily due to increased R&D investment in the current period | | Financial Expenses | 209,800.95 | -9,117,944.97 | 102.30% | Primarily due to adjustment of the term for proprietary wealth management products, recognized as investment income according to accounting standards | | Other Income | 6,874,919.88 | 2,839,488.23 | 142.12% | Primarily due to an increase in income-related government grants in the current period | | Investment Income | 5,970,483.04 | 2,496,771.49 | 139.13% | Primarily due to increased interest income from debt investments maturing in over 3 months | | Gains from Fair Value Changes | 15,500,390.17 | 11,704,736.35 | 32.43% | Primarily due to increased estimated unrealized gains from wealth management products | | Credit Impairment Losses | -967,456.45 | -2,295,759.74 | -57.86% | Primarily due to improved accounts receivable turnover in the current period, leading to a corresponding reduction in provisions | | Asset Impairment Losses | 73,241.81 | -5,017,063.97 | -101.46% | Primarily due to improved inventory turnover in the current period, leading to a corresponding reduction in asset impairment | | Gains from Asset Disposal | -47,648.67 | -291,393.48 | 83.65% | Primarily due to reduced disposal of fixed assets in the current period | | Non-Operating Income | 1,113,511.56 | 760,736.93 | 46.37% | Primarily due to increased non-operating intercompany income in the current period | | Non-Operating Expenses | 544,840.60 | 169,540.79 | 221.36% | Primarily due to increased non-operating intercompany expenses in the current period | Balance Sheet Items | Item | Period-End Balance (CNY) | Year-Beginning Balance (CNY) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 149,546,496.52 | 953,307,795.82 | -84.31% | Primarily due to the use of idle funds to purchase wealth management products in the current period | | Financial Assets Held for Trading | 1,080,865,642.40 | 122,474,089.44 | 782.53% | Primarily due to the use of idle funds to purchase wealth management products in the current period | | Financing for Receivables | 91,800.00 | | 100.00% | Primarily due to the receipt of bank acceptance bills from customers | | Other Current Assets | 13,497,779.71 | 136,601,545.89 | -90.12% | Primarily due to the maturity of debt investments maturing in over 3 months | | Construction in Progress | 2,934,035.77 | 5,515,050.76 | -46.80% | Primarily due to the completion and transfer of expansion projects to fixed assets | | Investments in Other Equity Instruments | 6,000,000.00 | | 100.00% | Primarily due to the investment in Huhuhu Health Technology (Hangzhou) Co., Ltd. in the current period | | Long-Term Deferred Expenses | 8,550,167.83 | 16,230,882.46 | -47.32% | Primarily due to the amortization of endorsement fees and renovation projects | | Deferred Income Tax Assets | 13,513,980.79 | 2,101,241.07 | 543.14% | Primarily due to an increase in deductible temporary differences for income tax at the end of the current period | | Taxes Payable | 31,452,011.77 | 8,185,662.07 | 284.23% | Primarily due to increased company profit and corresponding increase in income tax payable in the current period | | Other Current Liabilities | 24,780,273.28 | 15,261,367.96 | 62.37% | Primarily due to an increase in estimated returns corresponding to increased revenue | | Lease Liabilities | 891,503.80 | 3,311,030.03 | -73.07% | Primarily due to a decrease in lease liabilities as house rent was paid in the current period | | Deferred Income Tax Liabilities | 199,629.86 | 1,006,990.84 | -80.18% | Primarily due to a decrease in taxable temporary differences for income tax at the end of the current period | Cash Flow Statement Items | Item | YTD (CNY) | Prior Year Period (CNY) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Financing Activities | -74,379,994.83 | -54,761,291.73 | 35.83% | Primarily due to higher dividend distributions in the current period | [Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) This section details the total number of ordinary shareholders, the top ten shareholders' holdings, and information on restricted shares [Total Number of Ordinary Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings](index=4&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20Total%20Number%20of%20Ordinary%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the reporting period end, the company had 13,896 ordinary shareholders, with Shanghai Mingyue Industrial Co., Ltd. holding the largest stake at 55.09% and all restricted shares - The total number of ordinary shareholders was **13,896** at the end of the reporting period[12](index=12&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held | Number of Restricted Shares Held | | :--- | :--- | :--- | :--- | :--- | | Shanghai Mingyue Industrial Co., Ltd. | Domestic Non-State-Owned Legal Person | 55.09% | 111,004,500 | 111,004,500 | | Shanghai Nuoweiqi Positioning Investment Management Co., Ltd. - Ningbo Meishan Bonded Port Area Nuoweiqi Positioning Venture Capital Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 6.29% | 12,667,564 | 0 | | Xie Gongxing | Domestic Natural Person | 2.45% | 4,933,500 | 4,933,500 | | Xie Gongwan | Domestic Natural Person | 2.45% | 4,933,500 | 4,933,500 | | National Social Security Fund 504 Portfolio | Other | 1.85% | 3,729,830 | 0 | | Danyang Zhiming Enterprise Management Center (Limited Partnership) | Domestic Non-State-Owned Legal Person | 1.74% | 3,510,000 | 3,510,000 | | Zeng Zhe | Domestic Natural Person | 1.62% | 3,274,500 | 2,455,875 | | Zeng Shaohua | Domestic Natural Person | 1.22% | 2,467,500 | 2,467,500 | | Danyang Zhiyuan Enterprise Management Center (Limited Partnership) | Domestic Non-State-Owned Legal Person | 1.20% | 2,419,500 | 0 | | CSC Financial Co., Ltd. - China CITIC Bank - CSC Financial Mingyue Lens No. 1 Strategic Placement Collective Asset Management Plan | Other | 0.78% | 1,579,848 | 0 | - Xie Gongwan and Xie Gongxing are brothers, and Zeng Shaohua is the spouse of Xie Gongwan's sister; Xie Gongwan, Xie Gongxing, and Zeng Shaohua collectively hold **100%** of Shanghai Mingyue Industrial Co., Ltd.; Xie Gongxing is the executive partner of Danyang Zhiming Enterprise Management Center (Limited Partnership), thus Xie Gongwan, Xie Gongxing, Zeng Shaohua, Shanghai Mingyue Industrial Co., Ltd., and Danyang Zhiming Enterprise Management Center (Limited Partnership) are considered parties acting in concert[12](index=12&type=chunk) Zeng Zhe is the executive partner of Danyang Zhiyuan Enterprise Management Center (Limited Partnership), therefore Zeng Zhe and Danyang Zhiyuan Enterprise Management Center (Limited Partnership) are considered parties acting in concert[12](index=12&type=chunk) [Total Number of Preferred Shareholders and Top 10 Preferred Shareholders' Holdings](index=5&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20Total%20Number%20of%20Preferred%20Shareholders%20and%20Top%2010%20Preferred%20Shareholders%27%20Holdings) The company has no preferred shareholders - The company has no preferred shareholders[13](index=13&type=chunk) [Changes in Restricted Shares](index=5&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20Changes%20in%20Restricted%20Shares) No changes occurred in the company's restricted shares during the reporting period - The company's restricted share changes are not applicable, indicating no changes during the reporting period[13](index=13&type=chunk) [Other Significant Matters](index=5&type=section&id=III.%20Other%20Significant%20Matters) Despite a slow economic recovery, Mingyue Lens maintained resilient performance in Q3 with sustained main business growth, driven by successful product strategies, improved gross margins, new product launches, and strategic partnerships - Despite an unpronounced recovery in the macro economy and consumer market, the company maintained resilient performance with sustained growth in its main business during the reporting period[13](index=13&type=chunk) - Lens business revenue for the third quarter was **CNY 166.9054 million**, representing a **3.9% year-over-year increase** after excluding export business[13](index=13&type=chunk) - The company's focus on a "big single product" strategy yielded significant results, with PMC Super Bright series product revenue growing by **50.62%** and 1.71 series products by **16.5%** in the first three quarters[13](index=13&type=chunk) - The company's overall business gross margin for the first three quarters of 2024 was **59.30%**, an increase of **1.39 percentage points** compared to the same period last year[13](index=13&type=chunk) - The company launched its new generation Easy Control PRO2.0 series products, demonstrating a **73.82% effective rate** for equivalent spherical power after 12 months of wear, a significant improvement from PRO1.0's **60%**[13](index=13&type=chunk) - The company proactively recalled Easy Control PRO1.0 series products from channels to promote PRO2.0; excluding the impact of product upgrade and recall, third-quarter sales of the "Easy Control PRO" series products increased by **34.2% year-over-year**[13](index=13&type=chunk) - The company regularly conducted eye care public service campaigns on CCTV, organized summer promotions including Minions prize draws, movie screenings, and pop-up events, hosted expert science popularization courses, and expanded its presence on social media platforms like Douyin, Xiaohongshu, and Zhihu to empower and drive traffic to offline channels[14](index=14&type=chunk) - Mingyue and global optical giant Leica held the "New Vision Leica Eyecare China Launch Event," with future collaborations encompassing optical technology sharing, joint product R&D, and market channel expansion, aiming to enter the high-end lens market[14](index=14&type=chunk) [Quarterly Financial Statements](index=6&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section presents the company's consolidated balance sheet, income statement, and cash flow statement for the reporting period, offering a detailed view of its financial position, operating results, and cash movements [Financial Statements](index=6&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20Financial%20Statements) This section provides the company's consolidated balance sheet as of the end of the reporting period, and the consolidated income statement and cash flow statement from the beginning of the year to the end of the reporting period [Consolidated Balance Sheet](index=6&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of the reporting period end, total assets reached CNY 1.843 billion, a 5.15% increase from the beginning of the year, with a significant rise in financial assets held for trading and a corresponding decrease in cash and cash equivalents | Item | Period-End Balance (CNY) | Year-Beginning Balance (CNY) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 149,546,496.52 | 953,307,795.82 | | Financial Assets Held for Trading | 1,080,865,642.40 | 122,474,089.44 | | Accounts Receivable | 154,754,576.80 | 123,942,521.94 | | Inventories | 86,051,719.51 | 75,882,367.79 | | Total Current Assets | 1,509,571,781.17 | 1,435,931,851.17 | | Fixed Assets | 232,178,620.07 | 227,166,151.35 | | Intangible Assets | 45,864,345.78 | 39,813,725.91 | | Deferred Income Tax Assets | 13,513,980.79 | 2,101,241.07 | | Total Non-Current Assets | 333,492,195.27 | 316,812,093.75 | | Total Assets | 1,843,063,976.44 | 1,752,743,944.92 | | Accounts Payable | 45,122,304.75 | 58,521,563.04 | | Taxes Payable | 31,452,011.77 | 8,185,662.07 | | Other Current Liabilities | 24,780,273.28 | 15,261,367.96 | | Total Current Liabilities | 153,055,877.19 | 132,254,092.93 | | Total Liabilities | 165,399,651.30 | 149,206,399.59 | | Total Owner's Equity Attributable to Parent Company | 1,633,315,398.36 | 1,556,526,892.00 | | Total Owner's Equity | 1,677,664,325.14 | 1,603,537,545.33 | [Consolidated Income Statement from Year-Beginning to End of Reporting Period](index=8&type=section&id=2.%20Consolidated%20Income%20Statement%20from%20Year-Beginning%20to%20End%20of%20Reporting%20Period) From the beginning of the year to the end of the reporting period, total operating revenue was CNY 583.28 million, up 3.61% year-over-year, with net profit attributable to parent company shareholders reaching CNY 137.01 million, an 11.91% increase | Item | Amount for Current Period (CNY) | Amount for Prior Period (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 583,282,748.51 | 562,949,775.72 | | Total Operating Costs | 442,542,952.40 | 419,649,680.72 | | Operating Costs | 237,410,140.62 | 236,947,292.53 | | Selling Expenses | 110,413,909.02 | 112,497,467.78 | | Administrative Expenses | 64,655,835.53 | 55,813,475.72 | | R&D Expenses | 23,006,274.11 | 16,976,361.63 | | Financial Expenses | 209,800.95 | -9,117,944.97 | | Other Income | 6,874,919.88 | 2,839,488.23 | | Investment Income | 5,970,483.04 | 2,496,771.49 | | Gains from Fair Value Changes | 15,500,390.17 | 11,704,736.35 | | Operating Profit | 168,143,725.89 | 152,736,873.88 | | Total Profit | 168,712,396.85 | 153,328,070.02 | | Net Profit | 144,914,741.36 | 133,282,845.33 | | Net Profit Attributable to Parent Company Shareholders | 137,007,833.30 | 122,421,875.85 | | Basic Earnings Per Share | 0.6799 | 0.6075 | | Diluted Earnings Per Share | 0.6799 | 0.6075 | [Consolidated Cash Flow Statement from Year-Beginning to End of Reporting Period](index=10&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement%20from%20Year-Beginning%20to%20End%20of%20Reporting%20Period) Net cash flow from operating activities was CNY 138.42 million YTD, a slight decrease year-over-year, while investment activities saw a significant increase in cash outflows, and financing activities were negative due to higher dividend distributions | Item | Amount for Current Period (CNY) | Amount for Prior Period (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 138,419,622.55 | 143,534,071.82 | | Net Cash Flow from Investing Activities | -663,457,112.69 | -558,628,624.53 | | Net Cash Flow from Financing Activities | -74,379,994.83 | -54,761,291.73 | | Net Increase in Cash and Cash Equivalents | -599,465,807.42 | -469,576,768.79 | | Cash and Cash Equivalents at Period End | 88,705,526.20 | 464,429,321.13 | - Total cash outflow from investing activities was **CNY 2,747,246,387.10**, with cash paid for investments amounting to **CNY 2,697,000,000.00**, a substantial increase from the prior period[20](index=20&type=chunk) - Net cash flow from financing activities was negative, primarily due to higher dividend distributions in the current period, with cash paid for dividends, profits, or interest amounting to **CNY 70,788,765.86**[21](index=21&type=chunk) [Adjustments to Financial Statement Items at the Beginning of the First Year of New Accounting Standards Implementation from 2024](index=11&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20Adjustments%20to%20Financial%20Statement%20Items%20at%20the%20Beginning%20of%20the%20First%20Year%20of%20New%20Accounting%20Standards%20Implementation%20from%202024) The company did not adjust any financial statement items at the beginning of the year due to the first-time adoption of new accounting standards - The company did not adjust any financial statement items at the beginning of the first year of implementation due to the first-time adoption of new accounting standards[21](index=21&type=chunk) [Audit Report](index=11&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20Audit%20Report) This quarterly report is unaudited - The company's third-quarter report is unaudited[21](index=21&type=chunk)

证券代码：301101 证券简称：明月镜片 公告编号：2024-032 明月镜片股份有限公司 第二届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届董事会第十五次会议于 2024 年 10 月 22 日在公司会议室以现场结合通讯的表决方式召开。本次会议通知于 2024 年 10 月 10 日以专人送达、电话、微信的方式通知了全体董事。本次会议由董事长 谢公晚先生主持，应出席会议董事 6 人，实际参加会议董事 6 人，公司监事、高级 管理人员列席会议。会议召开符合《中华人民共和国公司法》、《公司章程》等规定， 会议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年第三季度报告>的议案》； 公司董事会审计委员会已审议通过该议案。 表决结果：6 票同意；0 票反对；0 票弃权。 （二）审议通过《关于补选第二届董事会非独立董事候选人的议案》； 公司董事会提名委员会已审议通过该议案。 同时，王雪平先生当选后 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-034 2024 年 10 月 24 日 附件 明月镜片股份有限公司（以下简称"公司"）于 2024 年 10 月 22 日召开了第 二届董事会第十五次会议，审议通过《关于补选第二届董事会非独立董事候选人的 议案》。鉴于公司原董事彭志云先生申请辞去公司董事及董事会战略与投资委员会 委员职务，公司董事会提名王雪平先生（简历详见附件）为公司第二届董事会非独 立董事候选人，王雪平先生将在当选董事后担任公司第二届董事会战略与投资委 员会委员的职务。王雪平先生担任上述职务的任期为自公司股东大会审议通过之 日起至公司第二届董事会任期届满之日止。 本次补选完成后，公司董事会中兼任高级管理人员的董事人数总计未超过公 司董事总数的二分之一，符合相关法律法规的规定。 特此公告。 明月镜片股份有限公司 董 事 会 明月镜片股份有限公司 关于补选第二届董事会非独立董事候选人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 非独立董事候选人简历 1、王雪平先生的简历 王雪平先生，1975 年生 ...

（一）审议通过《关于<2024 年第三季度报告>的议案》。 经审核，监事会认为：董事会编制和审核公司 2024 年第三季度报告的程序 符合法律、行政法规和中国证监会的规定，第三季度报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 证券代码：301101 证券简称：明月镜片 公告编号：2024-033 明月镜片股份有限公司 第二届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届监事会第十五次会议于 2024 年 10 月 22 日在公司会议室以现场表决方式召开。本次会议通知于 2024 年 10 月 10 日以专人送达、电话、微信等形式通知了全体监事。本次会议由监事会 主席朱海峰先生召集并主持，应出席公司会议的监事 3 人，实际出席公司会议的 监事 3 人。会议召开符合《中华人民共和国公司法》、《公司章程》等规定，会议 合法有效。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议通过议案如下： 监 事 会 2024 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-035 明月镜片股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 明月镜片股份有限公司（以下简称"公司"）于 2024 年 10 月 22 日召开的第 二届董事会第十五次会议审议通过了《关于召开公司 2024 年第二次临时股东大 会的议案》，决定于 2024 年 11 月 8 日（星期五）14:30 召开 2024 年第二次临时 股东大会，现将有关事项通知如下： 一、会议召开的基本情况 （一）会议届次：2024 年第二次临时股东大会 （二）会议召集人：董事会。公司第二届董事会第十五次会议于 2024 年 10 月 22 日召开，审议通过了《关于召开公司 2024 年第二次临时股东大会的议案》， 同意召开本次股东大会。 （三）会议召开的合法性及合规性：本次董事会召开股东大会会议符合有关 法律、行政法规、部门规章、规范性文件和《公司章程》的相关规定。 （四）会议召开日期、时间： 1、会议召开时间：2024 年 11 月 8 日（星期五）14:30 2、网络投票时间：2024 年 11 月 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-031 明月镜片股份有限公司 特此公告。 明月镜片股份有限公司 董 事 会 2024 年 9 月 11 日 明月镜片股份有限公司（以下简称"公司"）董事会于 2024 年 9 月 11 日收到 公司董事彭志云先生提交的书面辞职报告。彭志云先生由于个人原因，申请辞去担 任的公司董事、战略与投资委员会委员职务，辞职后不在公司及控股子公司担任其 他职务。彭志云先生原定董事任期为 2022 年 12 月 5 日至 2025 年 12 月 4 日。 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》相关的规定，彭志云先生的辞职未导致公司董事会成员人数低于 法定最低人数，亦未导致公司董事会中兼任公司高级管理人员的董事人数总计超 过公司董事总数的二分之一，其辞职报告自送达公司董事会之日起生效。彭志云先 生辞去上述职务不会对董事会的正常运作和公司生产经营产生影响。截至本公告 披露日，彭志云先生未持有公司股票，且不存在应当履行而未履行的承诺事项。 彭志云先生任职公司董事期间勤勉尽责，公司董事会对彭志云先生任职期间 为公司经营 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-030 东方证券已于近日自证监会取得换发后的《经营证券期货业务许可证》，业务 范围含"证券承销与保荐"。东方证券与东方投行严格根据有关法律法规、证监会 批复及相关要求推进实施吸收合并工作，自 2024 年 9 月 2 日起，东方投行存量客 户与业务整体迁移并入东方证券，东方投行承接的投资银行业务项目均由东方证 券继续执行，东方投行对外签署的协议均由东方证券继续履行，东方投行全部债权 及债务由东方证券依法承继。 公司持续督导保荐机构由东方投行变更为东方证券。本次持续督导保荐机构 主体变更事项不属于公司更换持续督导保荐机构事项。 特此公告。 明月镜片股份有限公司 董 事 会 2024 年 9 月 5 日 明月镜片股份有限公司 关于持续督导保荐机构主体变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 明月镜片股份有限公司（以下简称"公司"）近日接到公司首次公开发行股票 之持续督导机构东方证券承销保荐有限公司（以下简称"东方投行"）的通知，根 据中国证券监督管理委员会于 2023 年 2 月 2 ...

Investment Rating - The investment rating for the company is "Increase" (maintained) with a target price of 25.03 CNY [1]. Core Views - The company has shown resilience in its lens business, achieving a revenue increase of 12.08% in the first half of 2024, despite external pressures [1]. - The company's focus on star products has led to significant growth, with the PMC Ultra Bright series revenue increasing by 58.82% [1]. - The company has expanded its product matrix with new anti-blue light lens products, enhancing its competitive edge in the market [1]. Financial Performance - In Q2 2024, the company reported revenue of 193 million CNY, a decrease of 0.72% year-on-year, while net profit attributable to the parent company was 47 million CNY, an increase of 3.74% [1]. - For the first half of 2024, total revenue reached 385 million CNY, up 5.21% year-on-year, with net profit increasing by 11.04% to 89 million CNY [1]. - The company's gross margin improved to 59.40%, up 2.72 percentage points year-on-year, with a net profit margin of 24.43%, an increase of 0.68 percentage points [1]. Product and Market Strategy - The company has optimized its product structure and customer base, with direct sales accounting for 55.39% of total revenue in the first half of 2024 [1]. - The company has established an exclusive partnership with Leica, enhancing its brand strength and product advantages in the high-end lens market [1]. - The company continues to focus on differentiated lens categories, particularly in the youth myopia management sector, which is expected to drive significant growth in the future [1]. Financial Projections - The company has adjusted its profit forecast, expecting net profits of 180 million CNY, 210 million CNY, and 260 million CNY for 2024, 2025, and 2026 respectively [1]. - Earnings per share (EPS) are projected to be 0.89 CNY, 1.06 CNY, and 1.29 CNY for the same years, with corresponding price-to-earnings (P/E) ratios of 28, 24, and 19 times [1][2].

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company achieved a revenue of 385 million yuan in H1 2024, representing a year-on-year increase of 5.2%, and a net profit attributable to shareholders of 89 million yuan, up 11.0% year-on-year [1]. - The company continues to upgrade its product structure and expand its distribution channels, with significant growth in its "Easy Control" series, which saw sales of 76 million yuan in H1 2024, a 38.9% increase year-on-year [1]. - The company has established a strong market position in the defocus lens segment, with rapid growth and a focus on a "1+3" major product strategy [1][2]. Financial Performance - In Q2 2024, the company reported a revenue of 193 million yuan, a slight decrease of 0.7% year-on-year, while net profit increased by 3.7% to 47 million yuan [1]. - The gross margin for Q2 2024 was 60.7%, an increase of 3.6 percentage points year-on-year, driven by product structure upgrades and the rapid growth of defocus lenses [2]. - The company forecasts net profits of 170 million yuan, 210 million yuan, and 250 million yuan for 2024, 2025, and 2026, respectively, with corresponding P/E ratios of 29.2X, 24.1X, and 20.2X [2][3]. Product Development - The "Easy Control" series continues to perform well, with a significant increase in sales and a strong marketing push, including collaborations with popular brands and influencers [1]. - The company has entered into an exclusive partnership with Leica for lens development, aiming to enhance its presence in the high-end lens market [1]. Market Position - The company has solidified its leading position in the defocus lens market, with a notable increase in sales and market penetration [1][2]. - The revenue from the three major star products accounted for 55.79% of the regular lens revenue in H1 2024, indicating a successful product matrix strategy [1].